Does a diagnosis of metabolic syndrome have value in clinical practice

作者: Scott M Grundy

DOI: 10.1093/AJCN/83.6.1248

关键词:

摘要: "The metabolic syndrome" is the name for a clustering of risk factors cardiovascular disease and type 2 diabetes that are origin. These consist atherogenic dyslipidemia, elevated blood pressure, plasma glucose, prothrombotic state, proinflammatory state. There major, interacting causes syndrome-obesity endogenous susceptibility. The latter typically manifested by insulin resistance. syndrome accompanied 2-fold increase in 5-fold diabetes. A clinical diagnosis useful because it affects therapeutic strategy patients at higher risk. However, there views about best with syndrome. One view holds each should be singled out treated separately. other greater emphasis given to implementing therapies will reduce all simultaneously. approach emphasizes lifestyle (weight reduction increased exercise), which target factors. This also foundation targeting multiple together striking underlying causes, as development drugs promote weight Treating does not rule management individual factors, but add strength control

参考文章(19)
Stevo Julius, Silja Majahalme, Paolo Palatini, Antihypertensive treatment of patients with diabetes and hypertension American Journal of Hypertension. ,vol. 14, ,(2001) , 10.1016/S0895-7061(01)02237-3
C. Lorenzo, M. Okoloise, K. Williams, M. P. Stern, S. M. Haffner, The Metabolic Syndrome as Predictor of Type 2 Diabetes: The San Antonio Heart Study Diabetes Care. ,vol. 26, pp. 3153- 3159 ,(2003) , 10.2337/DIACARE.26.11.3153
Gerald M. Reaven, Banting lecture 1988 Nutrition. ,vol. 13, pp. 64- ,(1997) , 10.1016/0899-9007(97)90878-9
G. M. Reaven, Role of Insulin Resistance in Human Disease Diabetes. ,vol. 37, pp. 1595- 1607 ,(1988) , 10.2337/DIAB.37.12.1595
Terje R Pedersen, Ole Faergeman, John JP Kastelein, Anders G Olsson, Matti J Tikkanen, Ingar Holme, Mogens Lytken Larsen, Fredrik S Bendiksen, Christina Lindahl, Michael Szarek, John Tsai, Incremental Decrease in End Points Through Aggressive Lipid Lowering (IDEAL) Study Group, High-Dose Atorvastatin vs Usual-Dose Simvastatin for Secondary Prevention After Myocardial InfarctionThe IDEAL Study: A Randomized Controlled Trial JAMA. ,vol. 294, pp. 2437- 2445 ,(2005) , 10.1001/JAMA.294.19.2437
Scott M. Grundy, James I. Cleeman, Stephen R. Daniels, Karen A. Donato, Robert H. Eckel, Barry A. Franklin, David J. Gordon, Ronald M. Krauss, Peter J. Savage, Sidney C. Smith, John A. Spertus, Fernando Costa, Diagnosis and Management of the Metabolic Syndrome An American Heart Association/National Heart, Lung, and Blood Institute Scientific Statement Circulation. ,vol. 112, pp. 2735- 2752 ,(2005) , 10.1161/CIRCULATIONAHA.105.169404
Scott M Grundy, James I Cleeman, C Noel Bairey Merz, H Bryan Brewer Jr, Luther T Clark, Donald B Hunninghake, Richard C Pasternak, Sidney C Smith Jr, Neil J Stone, None, Implications of Recent Clinical Trials for the National Cholesterol Education Program Adult Treatment Panel III Guidelines Circulation. ,vol. 44, pp. 227- 239 ,(2004) , 10.1161/01.CIR.0000133317.49796.0E
K George MM Alberti, Paul Zimmet, Jonathan Shaw, The metabolic syndrome—a new worldwide definition The Lancet. ,vol. 366, pp. 1059- 1062 ,(2005) , 10.1016/S0140-6736(05)67402-8